Alnylam Pharmaceuticals, Inc. (ALNY)
| Previous close | 132.27 |
| Open | 132.07 |
| Bid | 130.47 x 900 |
| Ask | 131.56 x 800 |
| Day's range | 130.46 - 133.14 |
| 52-week range | 117.58 - 212.00 |
| Volume | |
| Avg. volume | 866,400 |
| Market cap | 15.889B |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.49 |
| Earnings date | 01 Aug 2022 - 05 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 207.85 |
- Business Wire
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
CAMBRIDGE, Mass., May 23, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The 18-month findings show that in a pre-defined cardiac subpopulation, treatment with vutrisiran was associated with improveme
- Zacks
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
- Business Wire
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
CAMBRIDGE, Mass., May 04, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
